Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Pacira BioSciences (PCRX) has granted inducement awards to six new employees on March 4, 2025, under its Amended and Restated 2014 Inducement Plan. The awards include:
- Stock options for 23,500 shares granted to five employees, with a 10-year term and exercise price of $23.53 per share
- 29,400 restricted stock units (RSUs) distributed among six employees
The stock options follow a four-year vesting schedule with 25% vesting on first employment anniversary and quarterly installments over 36 months thereafter. RSUs vest annually in four equal installments starting March 1, 2026. All awards require continued employment and were approved by the Compensation Committee under Nasdaq Listing Rule 5635(c)(4).
Pacira BioSciences (PCRX) ha concesso premi di incentivazione a sei nuovi dipendenti il 4 marzo 2025, nell'ambito del suo Piano di Incentivazione Modificato e Riformulato del 2014. I premi includono:
- Opzioni su azioni per 23.500 azioni concesse a cinque dipendenti, con un termine di 10 anni e un prezzo di esercizio di $23.53 per azione
- 29.400 unità azionarie vincolate (RSU) distribuite tra sei dipendenti
Le opzioni su azioni seguono un piano di maturazione di quattro anni, con il 25% che matura al primo anniversario di assunzione e rate trimestrali nei 36 mesi successivi. Le RSU maturano annualmente in quattro rate uguali a partire dal 1° marzo 2026. Tutti i premi richiedono un impiego continuativo e sono stati approvati dal Comitato per la Compensazione ai sensi della Regola di Quotazione Nasdaq 5635(c)(4).
Pacira BioSciences (PCRX) ha otorgado premios de incentivos a seis nuevos empleados el 4 de marzo de 2025, bajo su Plan de Incentivos Modificado y Reformulado de 2014. Los premios incluyen:
- Opciones sobre acciones para 23,500 acciones otorgadas a cinco empleados, con un plazo de 10 años y un precio de ejercicio de $23.53 por acción
- 29,400 unidades de acciones restringidas (RSU) distribuidas entre seis empleados
Las opciones sobre acciones siguen un calendario de adquisición de cuatro años, con un 25% que se adquiere en el primer aniversario de empleo y cuotas trimestrales durante los 36 meses siguientes. Las RSU se adquieren anualmente en cuatro cuotas iguales a partir del 1 de marzo de 2026. Todos los premios requieren empleo continuo y fueron aprobados por el Comité de Compensación bajo la Regla de Cotización Nasdaq 5635(c)(4).
Pacira BioSciences (PCRX)는 2025년 3월 4일에 수정 및 재정비된 2014년 유인 계획에 따라 여섯 명의 새로운 직원에게 유인 보상을 부여했습니다. 보상 항목은 다음과 같습니다:
- 다섯 명의 직원에게 부여된 23,500주에 대한 주식 옵션, 10년의 기간과 주당 $23.53의 행사 가격
- 여섯 명의 직원에게 분배된 29,400개의 제한 주식 단위(RSU)
주식 옵션은 4년의 취득 일정에 따라 첫 취업 기념일에 25%가 취득되고 이후 36개월 동안 분기별로 지급됩니다. RSU는 2026년 3월 1일부터 시작하여 연간 4개의 동일한 할부로 취득됩니다. 모든 보상은 지속적인 고용을 요구하며 Nasdaq 상장 규칙 5635(c)(4)에 따라 보상 위원회에서 승인되었습니다.
Pacira BioSciences (PCRX) a accordé des primes d'incitation à six nouveaux employés le 4 mars 2025, dans le cadre de son Plan d'Incitation Modifié et Révisé de 2014. Les primes comprennent :
- Options d'achat d'actions pour 23 500 actions attribuées à cinq employés, avec une durée de 10 ans et un prix d'exercice de $23.53 par action
- 29 400 unités d'actions restreintes (RSU) réparties entre six employés
Les options d'achat d'actions suivent un calendrier d'acquisition de quatre ans, avec 25 % d'acquisition à la première anniversaire d'emploi et des versements trimestriels sur 36 mois par la suite. Les RSU acquièrent annuellement en quatre versements égaux à partir du 1er mars 2026. Tous les prix nécessitent une poursuite de l'emploi et ont été approuvés par le Comité de Rémunération conformément à la Règle de Cotation Nasdaq 5635(c)(4).
Pacira BioSciences (PCRX) hat am 4. März 2025 Anreizpreise an sechs neue Mitarbeiter im Rahmen seines geänderten und neu gefassten Anreizplans von 2014 vergeben. Die Preise umfassen:
- Aktienoptionen für 23.500 Aktien, die an fünf Mitarbeiter vergeben wurden, mit einer Laufzeit von 10 Jahren und einem Ausübungspreis von $23.53 pro Aktie
- 29.400 eingeschränkte Aktieneinheiten (RSUs), die auf sechs Mitarbeiter verteilt sind
Die Aktienoptionen folgen einem vierjährigen Vesting-Zeitplan, wobei 25% am ersten Jahrestag der Anstellung und vierteljährliche Raten über die nächsten 36 Monate fällig werden. RSUs werden jährlich in vier gleichen Raten ab dem 1. März 2026 fällig. Alle Preise erfordern eine fortlaufende Beschäftigung und wurden vom Vergütungsausschuss gemäß der Nasdaq-Listing-Regel 5635(c)(4) genehmigt.
- None.
- None.
PARSIPPANY, N.J., March 06, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in the delivery of innovative, non-opioid pain therapies, today announced the granting of inducement awards on March 4, 2025 to six new employees under Pacira’s Amended and Restated 2014 Inducement Plan (the “Inducement Plan”) as a material inducement to each employee’s entry into employment with the company. In accordance with Nasdaq Listing Rule 5635(c)(4), the awards were approved by the Compensation Committee of the Board of Directors (the “Committee”) without stockholder approval.
Five employees received stock options to purchase an aggregate of 23,500 shares of Pacira common stock and six employees received restricted stock units for an aggregate of 29,400 shares of Pacira common stock. The stock options have a 10-year term and a four-year vesting schedule with 25 percent of the underlying shares vesting on the first anniversary of the recipient’s first day of employment and in successive equal quarterly installments over the 36 months thereafter. The stock options have an exercise price of
Vesting of the equity awards is subject to the employee’s continued employment with Pacira. Each equity award is also subject to the terms and conditions of an award agreement.
About Pacira
Pacira delivers innovative, non-opioid pain therapies to transform the lives of patients. Pacira has three commercial-stage non-opioid treatments: EXPAREL® (bupivacaine liposome injectable suspension), a long-acting local analgesic currently approved for infiltration, fascial plane block, and as an interscalene brachial plexus nerve block for postsurgical pain management; ZILRETTA® (triamcinolone acetonide extended-release injectable suspension), an extended-release, intra-articular injection indicated for the management of osteoarthritis knee pain; and iovera®º, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. The company is also advancing the development of PCRX-201, a novel locally administered gene therapy with the potential to treat large prevalent diseases like osteoarthritis. To learn more about Pacira, visit www.pacira.com.
FAQ
What is the vesting schedule for Pacira BioSciences (PCRX) inducement stock options granted in March 2025?
How many shares were included in PCRX's March 2025 inducement awards?
What is the exercise price for PCRX's March 2025 inducement stock options?
When do the restricted stock units (RSUs) granted by PCRX in March 2025 begin vesting?
